Share this article
Share this article
BILLERICA, Mass., Jan. 26, 2021 /PRNewswire/ Exogenesis nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, announced today the completion of production validation and sterilization validation as an immediate prelude to commercialization of Exogenesis nanoMesh™. The company anticipates first-in-man deployment of Exogenesis nanoMesh™ during the first quarter of 2021, followed immediately thereafter by national distribution. Exogenesis nanoMesh™ is an innovative soft tissue repair implant. Exogenesis nanoMesh™ possesses a unique nanometer-level surface texture, via the application of Accelerated Neutral Atom Beam (ANAB) technology
1 during manufacturing. Exogenesis nanoMesh™ is indicated for the repair of abdominal wall hernias and abdominal wall deficiencies that require the addition of reinforcing material to obtain the desired surgical result. Exogenesis nanoMesh™ is expected to be commercially available throughout the US